Xiao-I Corporation Announces Strategic Cooperation with Deafopia to Expand Market Outreach for AI Hardware Business
                    SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Xiao-I Corporation (NASDAQ: AIXI), a leading artificial intelligence company ("Xiao-I") , today announced a strategic cooperation with Deafopia, a nonprofit organization dedicated to supporting businesses within the deaf and hard-of-hearing communities. This collaboration will enhance the market visibility and distribution of Xiao-I's newly developed AI hardwares, with Deafopia managing outreach and expanding distribution...                
                
            Mom Favorite Brand Momcozy Showcases Cutting-Edge Products at Medtrade 2024
                    NEW YORK, March 25, 2024 /PRNewswire/ -- Medtrade 2024 attendees looking for mom-centric products now have a new option on the Expo Floor, Momcozy. The mom-oriented, global brand is dedicated to providing moms with smart parenting solutions. Momcozy will feature interactive demonstrations at its booth to give attendees a comprehensive overview of its award-winning breast pumps and breastfeeding essentials....                
                
            Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
                            OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals,...                
                
            Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results
                           CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 19, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced a positive profit alert for the six months ended June 30, 2024 (the...                
                
            MALAYSIA HEALTHCARE TRAVEL COUNCIL (MHTC) CONTINUES TO ENHANCE AND ELEVATE THEIR “EXPERIENCE MALAYSIA HEALTHCARE (EMH) STORIES” SERIES WITH EPISODE 3
                           KUALA LUMPUR, Malaysia, Aug. 8, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) continues their ongoing efforts to enhance and elevate their "Experience Malaysia Healthcare (EMH) Stories" with the third episode featuring Prof. Dato Sri Dr. Alwi Mohamed Yunus from Institut Jantung Negara (IJN). In this episode, Dr. Alwi shares with viewers his...                
                
            Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a...
                            European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melanoma...                
                
            Samsung Biologics launches development platforms for enhanced therapeutic efficacy
                            Samsung Biologics showcases new innovative development platforms – S-AfuCHOTM and S-OptiChargeTM – at BioProcess International 2024 New technology platforms to proactively address evolving industry trends and enable high-quality development  INCHEON, South Korea, Sept. 25, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), launched today...                
                
            KeyBioscience Announces Extension of Strategic Collaboration with Lilly
                           Companies to extend collaboration on DACRAs with an additional collaboration molecule and investigation of the DACRA platform within multiple indications LUGANO, Switzerland, Oct. 10, 2024 /PRNewswire/ -- KeyBioscience and Eli Lilly and Company have agreed to extend their collaboration on the development of Dual Amylin Calcitonin Receptor Agonists (DACRA), a new class of...                
                
            Vivance Completes Pre-Pivotal Trial of Wearable Dialysis Device; Results to be Shared at ASN Kidney Week 2024
                           SINGAPORE, Oct. 14, 2024 /PRNewswire/ -- Vivance, a leader in kidney care innovations, is proud to announce that the next trial phase of the wearable peritoneal dialysis (PD) device, Viva Kompact, has successfully concluded. The study was conducted at Singapore General Hospital (SGH), Singapore. The study data will be shared at American...                
                
            George Clinical Welcomes Tony Proctor as Chief Financial Officer
                    SINGAPORE, Dec. 2, 2024 /PRNewswire/ -- George Clinical, a leading global clinical research organisation, is pleased to announce the appointment of Tony Proctor, C.P.A., as Chief Financial Officer (CFO). With over 25 years of financial leadership experience, Tony brings a wealth of expertise in driving operational excellence, strategic planning, and transformational growth.   Tony Proctor, George Clinical, Chief...                
                
            